ReviewDrug design, development and therapy2022
Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma.
Review in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- Advanced Basal Cell Carcinoma in a Geriatric Patient: A Case Report and Ethical Considerations.Cureus · 2026Article
- Article
- Mohs Surgery vs. Wide Local Excision for Non-Melanoma Skin Cancer: Comparing Recurrence Rates, Economic Value, and Aesthetic Outcomes.Journal of cancer science and clinical therapeutics · 2026Article
- Basal Cell Carcinoma of the Cloacal Aperture in a Red Kangaroo (Veterinary sciences · 2025Article
- Clinical Features and Outcomes of Locally Advanced and Metastatic Basal Cell Carcinoma.Acta dermato-venereologica · 2025Article
- Combined cryotherapy and topical imiquimod, 5-fluorouracil, and tazarotene effectively treats locally advanced basal cell carcinoma and is associated with nearby nodular basal carcinoma regression.JAAD case reports · 2025Article
- Genetic Variations Related to Angiotensin II Production and Risk for Basal Cell Carcinoma.Biochemical genetics · 2025Review
- Article
- Palliative Radiotherapy to Preserve Eyesight in a Recurrent, Difficult-to-Treat Basal Cell Carcinoma.Cureus · 2025Article
- Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma.Journal of immunotherapy and precision oncology · 2024Article
- Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation.Cancers · 2024Review
- Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center.International journal of environmental research and public health · 2023Article
- Angiotensinogen, Angiotensin-Converting Enzyme, and Chymase Gene Polymorphisms as Biomarkers for Basal Cell Carcinoma Susceptibility.Advances in experimental medicine and biology · 2023Article
- Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients.Cancers · 2022Article
- Relationship between androgen receptor and epidermal growth factor receptor determines aggressive behavior of cutaneous basal cell carcinoma.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basal cell carcinoma (BCC) is the most common cancer in Caucasians, and its incidence continues to rise. Generally, BCCs have good outcomes when diagnosed and treated early. However, 1-10% of patients will develop advanced disease due to either delays in accessing treatment or aggressive tumors that may be refractory to treatment. Locally advanced basal cell carcinomas (laBCCs) are large, aggressive, or recurrent tumors that have the potential to invade surrounding tissues including bone, cartilage, nerve, and muscle. Treatment requires a multi-disciplinary approach where different modalities including surgery, radiation therapy, Hedgehog Pathway Inhibitors, and immunotherapy can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.